#United States #New York #digital health #DarioHealth #Research Studies

DarioHealth's Milestone: Over 100 Scientific Studies

DarioHealth Corp., a prominent name in global digital health, has announced an important milestone: it has crossed the threshold of 100 scientific studies, showcasing its commitment to delivering evidenced-based health outcomes for employers, health plans, and their members. This milestone not only highlights Dario’s extensive body of research but also positions it among the leading digital health vendors recognized for the volume and depth of scientifically validated evidence.

In the rapidly evolving landscape of healthcare, particularly digital health solutions, the demand for rigorous proof of impact is paramount. Employers and health plans are increasingly eyeing evidence beyond mere engagement metrics; they seek measurable impacts that reflect actual health improvements. DarioHealth's extensive research portfolio responds to this need, positioning the company as a trusted partner for organizations aiming to effectively reduce healthcare costs while enhancing health outcomes.

One of the most notable aspects of Dario's research is not just the sheer number of studies, but the rigorous methodologies employed. The company's portfolio includes independent research, large study populations that mirror real-world employer and health plan member bases, and longitudinal studies spanning several years. This breadth of evidence is augmented by multiple replicative studies validating critical health metrics, making DarioHealth’s findings particularly robust.

Dr. Omar Manejwala, Dario's Chief Medical Officer, emphasized, "For employers and health plans, evidence and scientific rigor are not optional—they are foundational." He pointed out that reaching the 100-study milestone showcases the durability and repeatability of Dario's health outcomes, with a substantial backing of scientific research. Outcomes from Dario’s research, such as claims reductions and measurable improvements in clinical metrics like HbA1c, are actual observations rather than theoretical projections. This empirical evidence adds to the credibility of Dario's offerings in the digital health sphere.

The company’s research has garnered significant visibility, with numerous publications featured in respected peer-reviewed platforms, underscoring Dario's evolution into a trusted partner in the healthcare industry. As healthcare purchasers transition towards value-based decision-making and vendor consolidation, DarioHealth's growing collection of peer-reviewed research continues to play a pivotal role in the conversation about practical, evidence-supported digital health solutions.

Within the diverse space of digital health, DarioHealth stands out by delivering personalized interventions for various conditions, including diabetes, hypertension, and behavioral health. By integrating user-centric designs with data analytics and ongoing coaching, the company has transformed how individuals with chronic conditions manage their health.

As DarioHealth moves forward, the goal remains to expand its portfolio of scientific evidence further, facilitating broader adoption of its solutions. Employers and health plans are showing heightened interest in these evidence-based digital health solutions, and Dario is poised to meet this increasing demand with innovative scientific research and effective, user-driven health interventions.

For more information on DarioHealth and its groundbreaking digital solutions, visit DarioHealth's website.

About DarioHealth

DarioHealth Corp. (NASDAQ DRIO) is revolutionizing chronic disease management through its digital therapeutics platform, designed to provide personalized, real-time interventions. Through innovative data analytics and individual coaching, DarioHealth gives people the tools they need to navigate their health journeys successfully, breaking away from the traditional episodic healthcare model.

Cautionary Note Regarding Forward-Looking Statements: This article includes forward-looking statements that may involve risks and uncertainties pertaining to expectations of future growth and research achievements, market acceptance, and the impact of competitive products. These factors should be considered carefully.